Integra LifeSciences (IART) announced the FDA 510(k) clearance for use of its Cusa Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Private Markets: Anthropic projects $70B in revenue in 2028
- Integra LifeSciences price target lowered to $13 from $15 at Truist
- Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements
- Integra LifeSciences price target raised to $13 from $12 at JPMorgan
- Integra LifeSciences price target lowered to $11 from $12 at Citi